DIRS.INFO The most relevant business & tech news

☆ Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
▼ + stars: | 2024-09-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +15 min

In this article ESALY4523.T-JPBIIB Follow your favorite stocks CREATE FREE ACCOUNTHannah Yoon | The Washington Post | Getty ImagesLeqembi, an Alzheimer's drug from Biogen and Eisai , isn't a cure for the mind-damaging disease. The drug works in part by clearing toxic plaques in the brain called amyloid, a hallmark of Alzheimer's, according to its manufacturers. The Mayo Clinic's center, which began screening patients for Leqembi in October, has 50 to 60 patients currently taking the drug, according to Petersen. The Mayo Clinic's Alzheimer's center similarly stops dosing patients if ARIA appears on an MRI, according to Petersen. Meeks' neurologist, Dr. Wendell Helveston, said a follow-up MRI picked up one small area of bleeding in her brain that didn't cause any symptoms.

Persons: Hannah Yoon, Missie Meeks, Meeks, Leqembi, I'm, haven't, Julio Rojas, Patricia Waldrup, Biogen's, Alzheimer's, Brian B, Bettencourt, Tracey Collins, Collins, Alex Scott, Scott, Medicare enrollees, Neurologists, Ronald Petersen, Jay Reinstein, Michael Robinson Chávez, Petersen, Michael Irizarry, Eisai's, Eisai, Biogen, Eisai's Scott, It's, Rojas, Wendell Helveston, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Washington Post, Getty, CNBC, University of California, San, San Francisco Health, Toronto Star, Medicare, Mayo Clinic Alzheimer's Disease Research, Georgetown University Hospital, Washington , D.C, Mayo, Leqembi, Mayo Clinic, Reuters, ARIA, Hattiesburg Clinic, Ave Locations: Biogen, Ellisville , Mississippi, U.S, San Francisco, Portland , Maine, Boston, South Mississippi, Washington ,, Mayo, Portland, South Portland, Mississippi, Eisai, Bartlett , Tennessee

☆ He Said He Was Ashamed of Storming the Capitol. Now He’s Running for Office.
▼ + stars: | 2024-06-10 | by ( Richard Fausset | ) www.nytimes.com time to read: +1 min

More than two years after Elias Irizarry breached the U.S. Capitol with other Trump supporters, he wrote a letter to Judge Tanya S. Chutkan as he waited for her to determine his sentence. “I want to make clear that I am not writing to make excuses or defend my actions,” he told Judge Chutkan, of Federal District Court in Washington. “My participation in an event like January 6th has brought great shame upon myself, my family, and, unfortunately, my country.”Today, Mr. Irizarry, a recent graduate of the Citadel, the renowned South Carolina military college, is mounting a primary challenge to a Republican in the state’s House of Representatives. His website recently noted his prosecution for engaging in “nonviolent activities” at the Capitol on Jan. 6 as proof that he has “always stood for the conservative movement.”“At every pivotal moment of the America First movement,” the website declared, “Elias has been there.”

Persons: Elias Irizarry, Tanya S, ”, Judge Chutkan, Irizarry, “ Elias Organizations: U.S, Capitol, Trump, Court, Citadel, South, Republican, Representatives Locations: Federal, Washington, South Carolina, state’s

☆ 7 tips to help you get a job in government contracting, according to recruiters
▼ + stars: | 2024-05-19 | by ( Ana Altchek | ) www.businessinsider.com time to read: +7 min

While lower pay in government jobs is sometimes viewed as a drawback of the sector, contracting companies tend to pay better than the federal government, and opportunities in this field are also increasing. Business Insider talked to three recruiters in the field to learn the best practices for getting a job in the industry. Make sure your clearances are up to dateMany government contracting roles require clearances, which can vary depending on the role and may also expire over time. Reach out to recruiters directlySince many government contracting opportunities have specific requirements, it can make a big difference to speak with a recruiter directly to find out what you need to do for that specific job. The site allows users to browse through thousands of open roles, many of which have contact info for recruiters.

Persons: —, Matt Grussendorf, Grussendorf, Lauren Irizarry, you've, Irizarry, it's, Quadesha Bynum, Bynum Organizations: Service, Business, Judge, —, Recruiting, Group, D.C, Employers Locations: Seattle, Southern California , Alabama, Denver

☆ 7 tips for looking for a job in government contracting, according to recruiters
▼ + stars: | 2024-05-19 | by ( Ana Altchek | ) www.businessinsider.com time to read: +7 min

Business Insider talked to three recruiters in the field to learn the best practices for getting a job in the industry. Make sure your clearances are up to dateMany government contracting roles require clearances, which can vary depending on the role and may also expire over time. Reach out to recruiters directlySince many government contracting opportunities have specific requirements, it can make a big difference to speak with a recruiter directly to find out what you need to do for that specific job. The site allows users to browse through thousands of open roles, many of which have contact info for recruiters. Grussendorf recommends reaching out to recruiters, talent acquisition at staffing agencies, or direct employers and telling them the job and salary range you're looking for to stay on their "candidate hot list."

☆ The world of government contract jobs is incredibly complex. Here are the basics.
▼ + stars: | 2024-04-21 | by ( Ana Altchek | ) www.businessinsider.com time to read: +7 min

This lets the government tackle specific jobs and projects quickly without all the steps of regular government hiring and bureaucratic obstacles. Thomson ReutersThere are a wide range of large government contracting companies that the government regularly makes deals with. John Breth, 40, worked in government contracting roles for 12 years before starting his own contracting company. If awarded the contract, you have to meet specific requirements set by the government, which may involve getting clearances or certifications. Once you understand the landscape better, you'll be able to recognize which jobs you qualify for and define your path forward.

Persons: —, Lockheed Martin, Lauren Irizarry, John Breth, Kevin Jennings, Jennings, you'll Organizations: Service, Department of Labor, Business, Raytheon, Thomson Reuters, Defense, Lockheed, Boeing, Northrop Grumman, Judge, US Small Business Administration Locations: Woburn, sba.gov

Toni Irizarry recognizes that the economy has improved. Compared with the first wave of the pandemic, when Las Vegas went dark, and joblessness soared to levels not seen since the Great Depression, these are days of relative normalcy. Ms. Irizarry, 64, oversees a cafe at the Orleans Hotel and Casino, a property just off the Las Vegas Strip that caters mostly to locals. Guests have returned, filling the blackjack and roulette tables amid the cacophony of jingling slot machines — the sound of money. Her paychecks have allowed her to purchase a home, raise three children and buy each of them their first car.

Persons: Toni Irizarry, Irizarry Organizations: Las Vegas, Orleans, Vegas Locations: Casino

☆ Judge Reinstates Murder Charge Against Ex-Philadelphia Police Officer for Deadly Traffic Stop
▼ + stars: | 2023-10-25 | by ( Oct. | At P.M. | ) www.usnews.com time to read: +2 min

(Reuters) - A Philadelphia appeals court judge reinstated charges of murder and other crimes against former police officer Mark Dial on Wednesday for fatally shooting a man as he sat in his car in August. Last month, Philadelphia's district attorney had charged Dial with murder and a host of other offenses for shooting Eddie Irizarry, 27, several times after Dial and another officer had slowly followed him through city streets. A few weeks later, Judge Wendy Pew of the Philadelphia Municipal Court dismissed the charges, citing a lack of evidence and agreeing with Dial's self-defense argument. Police had falsely said Irizarry had left his car and lunged at officers before the department admitted that was not the case. He has been charged with murder, voluntary manslaughter, aggravated assault, simple assault, recklessly endangering another person, and official oppression.

Persons: Mark Dial, Eddie Irizarry, Irizarry, Wendy Pew, Lillian Ransom, Dial, Jonathan Allen, Bill Berkrot Organizations: Reuters, Dial, Police, Philadelphia Municipal Court, Pennsylvania, Pleas, CBS, Philadelphia Police Department, CNN Locations: Philadelphia, Philadelphia's, Puerto Rico

The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai/Handout via REUTERS/File Photo Acquire Licensing RightsBOSTON, Oct 25 (Reuters) - An injected version of Eisai (4523.T) and Biogen's (BIIB.O) Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday. The Japanese drugmaker's review compared data for 72 patients with early Alzheimer's given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion. Blood concentration levels of the drug were 11% higher with subcutaneous Leqembi than the IV version. Roll-out of IV Leqembi, which has an annual list price of $26,500, has been slow.

Persons: Eisai, Leqembi, ”, Eric Reiman, Priya Singhal, Biogen, Michael Irizarry, Alzheimer's, Julie Steenhuysen, Deena Beasley, Bill Berkrot, Leslie Adler Organizations: Reuters, REUTERS, Rights, Banner Alzheimer's Institute, ARIA, Thomson Locations: Handout, Boston, Los Angeles

☆ Blood tests needed for widespread Alzheimer's diagnosis on the way
▼ + stars: | 2023-10-11 | by ( Deena Beasley | ) www.reuters.com time to read: +6 min

Several Alzheimer's blood tests are in the works – and one is already being sold to consumers – but none have been established as accurate, formally approved by regulators or reimbursed by insurers. Researchers have been working for years on blood tests for Alzheimer's that can replicate these diagnostic tools. The need for blood tests has become more pressing since the FDA approved Leqembi in July. Accurate blood tests are expected to help identify which dementia patients actually have Alzheimer’s, the most common but not the only cause of dementia. "When there are widely available, scalable, sensitive and specific blood tests it will be an absolute game changer for Alzheimer's patients."

Persons: Denis Balibouse, Eli Lilly, Dr, Sarah Kremen, Eliezer Masliah, Eisai, Michael Irizarry, Roche, Bruce Jordan, Russ Paulsen, Deena Beasley, Caroline Humer, Bill Berkrot Organizations: Memory Centre, of Readaptation, University Hospital, REUTERS, FDA, Sinai Medical Center, Wednesday, Quest Diagnostics, National Institute, Aging, U.S . National Institutes of Health, C2N Diagnostics, Roche Diagnostics, Alzheimer's Association, RAND, Thomson Locations: Geneva, Switzerland, Leqembi, Eisai, Los Angeles, U.S

☆ Philadelphia Police Officer Charged in Fatal Shooting
▼ + stars: | 2023-09-08 | by ( Remy Tumin | More About Remy Tumin | ) www.nytimes.com time to read: +1 min

A Philadelphia police officer was charged with murder after he fatally shot a 27-year-old man who was in his car at near point-blank range, prosecutors announced on Friday, weeks after top police officials announced that body camera footage of the killing showed a different account than what the officer initially described. Dial fatally shot Mr. Irizarry around noon on Aug. 14 after what the police initially said was a car chase ending in Mr. Irizarry lunging at them with a knife. But police officials said two days later that body camera footage showed that the man was still in his car when the officer shot him. The fatal shooting and changing account sparked community anger and protests. In an unusual move, Judge Christian DiCicco of the Philadelphia Municipal Court set bail for Mr.

Persons: Mark Dial, Eddie Irizarry, Dial, Irizarry, Christian DiCicco Organizations: Philadelphia Municipal Locations: Philadelphia

☆ New Alzheimer’s drug shows promise in slowing disease but may contain significant risks, study shows
▼ + stars: | 2022-11-30 | by ( The Associated Press | ) www.nbcnews.com time to read: +5 min

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much difference that might make in people’s lives. Now the companies are providing full results of the study of nearly 1,800 people in the earliest stages of the mind-robbing disease. Also, lecanemab recipients were 31% less likely to advance to the next stage of the disease during the study. The trial is important because it shows a drug that attacks a sticky protein called amyloid — considered one of several culprits behind Alzheimer’s — can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer’s Association. Eisai said Tuesday the deaths can’t be attributed to the Alzheimer’s drug.

☆ Experimental Alzheimer's drug: After promising data, experts say many questions remain
▼ + stars: | 2022-10-04 | by ( Brenda Goodman | ) edition.cnn.com time to read: +10 min

CNN —The experimental Alzheimer’s drug lecanemab made big news last week when the companies testing it released trial results that showed the drug met its goals, making it one of the first dementia drugs to return positive results. By some counts, lecanemab is the 16th drug that’s been developed to clear toxic amyloid plaques from the brain. Or did the companies that are testing it – Biogen and Eisai – run a smarter clinical trial that finally showcased the potential of these kinds of medications? Clinical trial results were mixed, with only one showing a small benefit to patients. He says he might change his mind if analysis of the clinical trial shows that one group of people got more of a benefit than others.

Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. read morePatient advocacy groups hailed the news of positive lecanemab trial results. Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

☆ Biogen's latest clinical trial is inching towards the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
▼ + stars: | 2022-09-19 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +7 min

It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said. Negative results might give a boost to companies that are exploring alternate ways to treat Alzheimer's disease. And though Biogen's drug is furthest along in development, it's far from being the only treatment being tested for Alzheimer's.

Search resuls for: "Irizarry"

14 mentions found